Candid Health Secures Series C Funding — Implications for RCM Automation

Candid Health has secured a Series C venture capital financing round, with Lowenstein Sandler LLP representing the revenue cycle automation platform. This funding marks a significant milestone for the company, enhancing its capabilities in the healthcare revenue cycle space and enabling further innovation in automation solutions.

The Deal

The Series C financing round raised an undisclosed amount reportedly in the tens of millions, with participation from existing and new investors. This round follows a successful Series B, solidifying Candid Health's growth trajectory. The deal is expected to close by the end of the quarter.

What It Means for RCM

Candid Health's increased funding will likely accelerate the development of more sophisticated automation tools, improving efficiency in billing operations.
Enhanced automation can lead to reduced days in AR and lower denial rates, benefiting providers financially.
The move may signal a shift towards more integrated revenue cycle solutions as competitors in the market respond to the growing demand for automation.

Market Context

The venture capital landscape for healthcare revenue cycle management continues to flourish, with increasing investments aimed at innovative solutions that streamline operations and enhance financial performance. As more companies attract funding, the competitive landscape is set to evolve, pushing traditional RCM models to adapt or risk obsolescence.

Published by RevCycleAI Research · May 29, 2026